Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.37 |
| ▸ | FEN1 | P39748 | 4/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.37 |
| ▸ | PI4KA | P42356 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702764 | 0.89 | CYP3A4 (0.57) | CYP3A4PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2450318 | 0.84 | CYP3A4 (0.51) | CYP3A4PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12302402 | 0.82 | CYP3A4 (0.49) | CYP3A4FEN1PIK3CGPIK3CDPIK3CA | |
| SCHEMBL12302501 | 0.82 | CYP3A4 (0.39) | CYP3A4KIT | |
| SCHEMBL2447905 | 0.81 | MAP3K11 (0.41) | CYP3A4KITALOX5APFEN1PIK3CG | |
| SCHEMBL13046826 | 0.80 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL2444702 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2C9 | |
| SCHEMBL1702611 | 0.78 | CYP3A4 (0.39) | CYP3A4KITPIK3CDCYP2D6CYP2C9 | |
| SCHEMBL1702882 | 0.78 | CYP3A4 (0.42) | CYP3A4CYP2C9 | |
| SCHEMBL1703333 | 0.78 | CYP3A4 (0.42) | CYP3A4PIK3CACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| EP-2440528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | claimed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | CYP3A4 50/4885KIT 3567/4885NR3C1 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.